Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Cardiff Oncology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.459 Welcome to the Cardiff Oncology fourth quarter 2024 financial results 00:00:05.459 -- 00:00:10.806 and business update conference call. At this time, all participants are in a 00:00:10.806 -- 00:00:15.873 listen-only mode. After the speaker's presentation, there will be a question 00:00:15.873 -- 00:00:20.600 and answer session. To ask a question during the session, you will need to press star 00:00:20.600 -- 00:00:25.727 11 on your telephone, and you will then hear an automated message advising your hand 00:00:25.727 -- 00:00:30.254 is raised. Please be advised that today's conference is being recorded. 00:00:30.254 -- 00:00:35.739 I would now like to turn the conference call over to Kiki Patel of Gilman Group. 00:00:35.739 -- 00:00:39.903 Oh, sorry, Gilmartin Group, my reading. Please go ahead. 00:00:39.903 -- 00:00:41.605 Thank 00:00:41.605 -- 00:00:46.770 you, operator. Joining us on the call today, from Cardiff Oncology, our Chief Executive 00:00:46.770 -- 00:00:50.854 Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine. 00:00:50.854 -- 00:00:55.539 During the conference call, management will make forward-looking statements, including 00:00:55.539 -- 00:01:00.892 without limitation, statements related to guidance, results, and timing of data readouts 00:01:00.892 -- 00:01:05.800 for OnVansertib clinical trials. These forward-looking statements are based on the company's 00:01:05.800 -- 00:01:11.168 current expectations and inherently involve significant risks and uncertainties. 00:01:11.168 -- 00:01:16.096 Our actual results and the timing of events could differ materially from those anticipated 00:01:16.096 -- 00:01:20.795 in such forward-looking statements as a result of these risks and uncertainties. 00:01:20....